GEN Exclusives

More »

GEN Poll

More »
Feb 06, 2012

FDA on Biosimilars

No interferon beta biosimilars are yet on the market in Europe, but EMA is preparing for that eventuality by soliciting formal comment on a draft guidance it issued January 23. There are two interferon beta-1a drugs—Biogen Idec’s Avonex and Merck Serono’s Rebif—and two interferon beta-1b drugs—Betaseron made by Bayer HealthCare and Novartis’ Extavia, a copy of Betaseron that Novartis pays Bayer royalties to market. The EMA has slowly but surely developed guidelines for different types of biosimilars, while FDA is still working on finalizing the pathway for biosimilar approval in the U.S. The agency says it is in the final stages of issuing a draft guidance, though. What do you think of the situation in the U.S.?

How satisfied are you with progress toward bringing biosimilars to the U.S. market?

Very
 
  15.7%
Somewhat
 
  13.7%
Not Much
 
  62.7%
Undecided
 
  7.8%

More Polls » View Results »

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?